Skip to main content

Danaher Corporation

corporate_fare Company Profile

Danaher Corporation

DHR·NYSE·Life Sciences·CIK 0000313616

Danaher is a global science and technology innovator focused on improving human health. The company operates through more than 15 operating companies, which hold leadership positions in the biotechnology, life sciences, and diagnostics sectors. These businesses are organized into three segments: Biotechnology, Life Sciences, and Diagnostics. Danaher's businesses typically sell a high level of products and services on a recurring basis, primarily through a direct sales model, to a geographically diverse customer base. The company's research and development, manufacturing, sales, distribution, service, and administrative facilities are located in approximately 50 countries. Danaher aims to create shareholder value by strengthening its competitive advantage through the DANAHER BUSINESS SYSTEM ("DBS") tools and culture, enhancing its portfolio in attractive science and technology markets through strategic capital allocation, and consistently attracting and retaining exceptional talent. The company measures its progress against these priorities over the long-term using financial metrics related to revenue growth, profitability, cash flow, and capital returns, as well as certain non-financial metrics. Danaher acquires businesses and makes investments that either complement its existing portfolio or expand into new attractive markets. It also continually assesses the strategic fit of its existing businesses and may separate or dispose of businesses based on strategic and other considerations.

Danaher Corporation (NYSE:DHR) is a publicly traded company in the Life Sciences sector. Wiseek monitors DHR SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Danaher Seeks Shareholder Approval for Expanded Equity Incentive Plan and Increased Executive Compensation
  • Danaher Reports Mixed 2025 Results with Profit Decline Amid Revenue Growth; Confirms $9.9B Masimo Acquisition
  • Danaher to Acquire Masimo Corporation for $9.9 Billion, Expanding Diagnostics Portfolio
  • Danaher Reports Better-Than-Expected Q4 2025 Results and Issues Solid 2026 Guidance
  • Danaher Anticipates Q4 2025 Results Ahead of Expectations and Provides Positive 2026 Outlook

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$24.57B
Net Income
$3.61B
Diluted EPS
$5.05
Op. Cash Flow
$6.42B
Free Cash Flow
$5.26B
Gross Profit
$14.52B
Operating Income
$4.69B
Cash & Equivalents
$4.62B
Total Debt
$18.42B
Debt / Equity
0.35×
Net Margin
14.7%
Shares Outstanding
706.9M sh
Source: 10-K · filed 2026-02-24 · accession 0000313616-26-000062
$200.73 +4.23% today
52-week range · as of 2026-07-20 $160.93 – $242.8
Market cap
$139.93B
Volume
9.4M (1.6× avg)
3-mo avg 5.8M
Live data · 2026-07-29 09:24 UTC · Pre-market

show_chartPrice Chart

Loading chart...

feed DHR - Filings & News (Page 2)

DHR
Mar 25, 2026, 8:09 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $190.08
Real-time Price: $200.73 info
Change: +$10.65 (+6%) info
Market Cap: $139.929B info
DHR
Feb 24, 2026, 4:36 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $209.23
Real-time Price: $200.73 info
Change: -$8.50 (-4%) info
Market Cap: $139.929B info
DHR
Feb 17, 2026, 8:08 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $200.30
Real-time Price: $200.73 info
Change: +$0.430 (+0.21%) info
Market Cap: $139.929B info
DHR
Jan 27, 2026, 5:37 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $235.50
Real-time Price: $200.73 info
Change: -$34.77 (-15%) info
Market Cap: $139.929B info
DHR
Jan 12, 2026, 9:07 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $238.02
Real-time Price: $200.73 info
Change: -$37.29 (-16%) info
Market Cap: $139.929B info